Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ryan Confer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- -0.97
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -16.44
Financials
Net Income
$-4.45MEBITDA
$-4.45MFree Cash Flow
$-5.14MEPS (diluted)
$-9.40Shares Outstanding (diluted)
473.2K+965536.7%Operating Expenses
$4.48MCash & Debt
$15.15MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-16.23M | $-382.80 |
| 2024 | $0.00 | $-21.11M | $-5872.98 |
| 2023 | $0.00 | $-30.86M | $-24838.00 |
| 2022 | $0.00 | $-23.74M | $-21780.00 |
| 2021 | $0.00 | $-20.66M | $-19305.00 |
| 2020 | $0.00 | $-17.94M | $-22198.00 |
| 2019 | $0.00 | $-10.65M | $-29304.00 |
| 2018 | $0.00 | $-12.37M | $-39567.00 |
| 2017 | $0.00 | $-3.31M | $-12705.00 |
| 2016 | $0.00 | $-4.13M | $-16830.00 |
| 2015 | $0.00 | $-1.07M | $-25575.00 |
Valuation
GNPXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
103+29.17%Social Signal Score
Mentions (3)
- Newsprnewswire.com·6h ago·Neutral
…ings suggest that TUSC2 may play a foundational role in brain health AUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associate…
View source ↗ - Newsprnewswire.com·43d ago·Neutral
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference Company Presentation to Highlight Lead Clinical Oncology Program and Preclinical Diabetes Program AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C.
View source ↗ - Newsprnewswire.com·64d ago·Negative
…sses for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading U.S. based clinical and commercial Contract Development and Manufacturing Organization (CDMO) to initiate …
View source ↗
Earnings
Wed, Dec 2(in 6 weeks)
Consensus estimate $-6160.00 per share
Typical surprise -411.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Mar 30$-25.30 vs $-286.00beat
- Fri, Nov 14$-109.89 vs $-275.00beat
- Fri, Aug 8$-187.00 vs $-15.62miss
- Mon, May 12$-285.71 vs $-55.88miss
- Tue, Apr 1$-462.00 vs $-18.04miss
Estimates and results for GNPX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GNPX officers and directors.
- Bought
- $105k
- Sold
- $22
4 trades
2 trades
- Longnecker Brent Msold
- Longnecker Brent Msold
- Varner John Rodneybought
- Vaczy Catherine Mbought
- Longnecker Brent Mbought
- Varner John Rodneybought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tim Moorehouse · NC14 · disclosed Feb 23, 2026 (18d later)Buy$1,001 - $15,000
- Tim Moorehouse · NC14 · disclosed Jan 8, 2026 (21d later)Buy$1,001 - $15,000
- Tim Moorehouse · NC14 · disclosed Dec 3, 2025 (26d later)Buy$1,001 - $15,000
- Tim Moorehouse · NC14 · disclosed Nov 12, 2025 (14d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.